Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 9/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428734 | 1.00 | PDK2 (0.39) | PDK2CYP3A4NR3C1SIRT2CYP2C9 | |
| SCHEMBL1492614 | 1.00 | PDK2 (0.39) | PDK2CYP3A4NR3C1SIRT2CYP2C9 | |
| SCHEMBL1492621 | 0.88 | TAS2R14 (0.39) | PDK2 | |
| SCHEMBL1492625 | 0.88 | TAS2R14 (0.39) | PDK2 | |
| SCHEMBL1716823 | 0.88 | TAS2R14 (0.39) | PDK2 | |
| Formic Acid SCHEMBL1954948 | 0.85 | TAS2R14 (0.37) | PDK2 | |
| SCHEMBL1954947 | 0.82 | PDK2 (0.32) | PDK2 | |
| SCHEMBL1716402 | 0.77 | NR3C1 (0.33) | PDK2NR3C1 | |
| SCHEMBL1716857 | 0.76 | ALDH1A1 (0.33) | — | |
| SCHEMBL1716028 | 0.76 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268859-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20090325988-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325988-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | NR3C1, NR3C2, MC2R | PDK2 3048/4885CYP3A4 360/4885NR3C1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.